<DOC>
	<DOCNO>NCT02504008</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , 24-week study evaluate efficacy safety AXS-02 patient CRPS-I .</brief_summary>
	<brief_title>CREATE-1 : A Study Assess Efficacy Safety AXS-02 Patients With CRPS-1</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Complex Regional Pain Syndromes</mesh_term>
	<mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Key Male female least 18 year age Recently confirm diagnosis CRPS1 ( Budapest criterion ) Average pain intensity score â‰¥ 5 ( base 11point scale [ 0 10 ] ) Willing able provide write informed consent Key Received chronic opioid therapy within 4 week Received sympathetic nerve block within 3 week Active litigation pending worker ' compensation decision Any clinically significant medical pain condition ( eg , Parkinson 's disease , cognitive impairment , fibromyalgia ) clinical laboratory abnormality would investigator 's judgment interfere subject 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>bisphosphonate</keyword>
	<keyword>CRPS</keyword>
	<keyword>RSD</keyword>
	<keyword>non-opioid</keyword>
	<keyword>CRPS-1</keyword>
	<keyword>acute chronic pain</keyword>
	<keyword>chronic pain</keyword>
	<keyword>zoledronic acid</keyword>
</DOC>